SELECT Trial: Semaglutide’s Impact on MACE and Weight Loss
The SELECT trial demonstrates that semaglutide significantly reduces major adverse cardiovascular events (MACE) in overweight adults with established heart disease. Crucially, this benefit is not solely driven by weight loss, ... Read More